

May 16, 2002

To; All Parties Concerned

Company: Taisho Pharmaceutical Co., Ltd.  
Head Office: 24-1, Takata 3-Chome, Toshima-ku,  
Tokyo  
Representative: Akira Uehara, President  
(First Section of the Tokyo Stock  
Exchange: Ticker Code 4535)  
Contact: Takashi Shibata, Manager of  
Public Relations Section

## **Notification of Treasury Stock Purchase**

(Purchases of its treasury stock pursuant to Article 210 of the Commercial Code of Japan)

Taisho Pharmaceutical hereby announces that, in accordance with Article 210 of the Commercial Code, it is to make a proposal for authorization to purchase its treasury stock. The proposal will be placed on the agenda of its 93rd ordinary general meeting of shareholders to be held on June 27 2002.

### 1. Purpose of Stock Purchase

- (1) To provide the Company's shareholders with a profit by raising our capital efficiency and reducing the number of outstanding shares of common stock
- (2) To enable flexible financial administration that responds to business expansion

### 2. Details of Stock Purchase

- (1) Type of stock: Taisho par-value common stock
- (2) Amount of stock: 15,000,000 shares (upper limit)  
(Proportion of total outstanding shares; 4.40%)
- (3) Total value of stock: ¥40.0 billion (upper limit)

Notes: The Company would carry out the market purchase of common stock upon approval at the 93rd ordinary general meeting of shareholders to be held on June 27, 2002 and end the purchase after the 94th ordinary general meeting of shareholders to be closed.